TRAF-mediated regulation of immune and inflammatory responses

Science China Life Sciences

Volumn 53, Issue 2, 2010, Pages 159-168

  Wang, Ya Ya ^a   Zhang, Peng ^b   Liu, Ying Fang ^b   Cheng, Gen Hong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Innate immunity; NF B; TRAF; Type 1 interferon

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; PROTEIN BINDING;

ANIMAL; CHEMICAL STRUCTURE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1; MODELS, MOLECULAR; NF-KAPPA B; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

MAMMALIA;

EID: 77949285180     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-0050-3     Document Type: Review

References (81)

1. Rothe M, Wong S C, Henzel W J, et al. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell, 1994, 78: 681-692.
2. Hu H M, O'Rourke K, Boguski M S, et al. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem, 1994, 269: 30069-30072.
3. Cheng G, Cleary A M, Ye Z S, et al. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science, 1995, 267: 1494-1498.
4. Sato T, Irie S, Reed J C. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett, 1995, 358: 113-118.
5. Bradley J R, Pober J S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene, 2001, 20: 6482-6491.
6. Chung J Y, Park Y C, Ye H, et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sc, 2002, 115: 679-688.
7. Pineda G, Ea C K, Chen Z J. Ubiquitination and TRAF signaling. Adv Exp Med Biol, 2007, 597: 80-92.
8. Bishop G A. The multifaceted roles of TRAFS in the regulation of B-cell function. Na. Rev Immunol, 2004, 4: 775-786.
9. Park Y C, Burkitt V, Villa A R, et al. Structural basis for self-association and receptor recognition of human TRAF2. Nature, 1999, 398: 533-538.
10. Arch R H, Thompson C B. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol, 1998, 18: 558-565.
11. McWhirter S M, Pullen S S, Holton J M, et al. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA, 1999, 96: 8408-8413.
12. Ni C Z, Welsh K, Zheng J, et al. Crystallization and preliminary X-ray analysis of the TRAF domain of TRAF3. Acta Crystallogr D, 2002, 58: 1340-1342.
13. Song Y J, Izumi K M, Shinners N P, et al. IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc Natl Acad Sci USA, 2008, 105: 18448-18453.
14. Li C, Ni C Z, Havert M L, et al. Downstream regulator TANK binds to the CD40 recognition site on TRAF3. Structure, 2002, 10: 403-411.
15. Ni C Z, Oganesyan G, Welsh K, et al. Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol, 2004, 173: 7394-7400.
16. Xu Z, Nie P, Sun B, et al. 2007 Molecular identification and expression analysis of tumor necrosis factor receptor-associated factor 2 in grass carp Ctenopharyngodon idella. Acta Biochim Biophys Sin, 2007, 39: 857-868.
17. Ye H, Arron J R, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature, 2002, 418: 443-447.
18. Yin Q, Lin S C, Lamothe B, et al. E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol, 2009, 16: 658-697.
19. Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell, 2000, 103: 351-361.
20. Shi C S, Kehrl J H. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J Biol Chem, 2003, 278: 15429-15434.
21. Hostager B S, Haxhinasto S A, Rowland S L, et al. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem, 2003, 278: 45382-45390.
22. Xu Z, Devlin K I, Ford M G, et al. Structure and interactions of the helical and U-box domains of CHIP, the C terminus of HSP70 interacting protein. Biochemistry, 2006, 45: 4749-4759.
23. Zhang M, Windheim M, Roe S M, et al. Chaperoned ubiquitylation-crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol Cell, 2005, 20: 525-538.
24. Brown K D, Hostager B S, Bishop G A. Regulation of TRAF2 signaling by self-induced degradation. J Biol Chem, 2002, 277: 19433-19438.
25. Hayden M S, Ghosh S. Shared principles in NF-kappaB signaling. Cell, 2008, 132: 344-362.
26. Chen G, Goeddel D V. TNF-R1 signaling: a beautiful pathway. Science, 2002, 296: 1634-1635.
27. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 2003, 114, 181-190.
28. Ea C K, Deng L, Xia Z P, et al. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell, 2006, 22: 245-257.
29. Wu C J, Conze D B, Li T, et al. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol, 2006, 8: 398-406.
30. Kanayama A, Seth R B, Sun L, et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell, 2004, 15: 535-548.
31. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol, 2000, 18: 621-663.
32. Lee T H, Shank J, Cusson N, et al. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem, 2004: 279, 33185-33191.
33. Bertrand M J, Milutinovic S, Dickson K M, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell, 2008, 30: 689-700.
34. Vince J E, Pantaki D, Feltham R, et al. TRAF2 must bind to cIAPs for TNF to efficiently activate NF-{kappa}B and to prevent TNF-induced apoptosis. J Biol Chem, 2009, 284: 35906-35915.
35. Pomerantz J L, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. Embo J, 2009, 18: 6694-6704.
36. Bonnard M, Mirtsos C, Suzuki S, et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. Embo J, 2000, 19: 4976-4985.
37. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity, 2004, 21: 477-489.
38. Bishop G A. The multifaceted roles of TRAFs in the regulation of B-cell function. Nat Rev Immunol, 2004, 4: 775-786.
39. Hsing Y, Hostager B S, Bishop G A. Characterization of CD40 signaling determinants regulating nuclear factor-kappa B activation in B lymphocytes. J Immunol, 1997, 159: 4898-4906.
40. Pullen S S, Dang T T, Crute J J, et al. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem, 1999, 274: 14246-14254.
41. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med, 2007, 13: 460-469.
42. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol, 2003, 15: 396-401.
43. Cao Z, Xiong J, Takeuchi M, et al. TRAF6 is a signal transducer for interleukin-1. Nature, 1996, 383: 443-446.
44. Takatsuna H, Kato H, Gohda J, et al. Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling. J Biol Chem, 2003, 278, 12144-12150.
45. Conze D B, Wu C J, Thomas J A, et al. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation. Mol Cell Biol, 2008, 28: 3538-3547.
46. Qian Y, Commane M, Ninomiya-Tsuji J, et al. IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B. J Biol Chem, 2001, 276: 41661-41667.
47. Takaesu G, Kishida S, Hiyama A, et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell, 2000, 5: 649-658.
48. Karin M, Greten F R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 2005, 5: 749-759.
49. Wang Y, Tang Y, Teng L, et al. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol, 2006, 7: 139-147.
50. Caamaño J H, Rizzo C A, Durham S K, et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med, 1998, 187: 185-196.
51. Franzoso G, Carlson L, Poljak L, et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med, 1998, 187: 147-159.
52. Futterer A, Mink K, Luz A, et al. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity, 1998, 9: 59-70.
53. Rennert P D, James D, Mackay F, et al. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity, 1998, 9: 71-79.
54. Yilmaz Z B, Weih D S, Sivakumar V, et al. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J, 2003, 22: 121-130.
55. Shinkura R, Kitada K, Matsuda F, et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet, 1999, 22: 74-77.
56. Yin L, Wu L, Wesche H, Arthur C D, et al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science, 2001, 291: 2162-2165.
57. Annunziata C M, Davis R E, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell, 2007, 12: 115-130.
58. Keats J J, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 2007, 12: 131-144.
59. Zarnegar B J, Wang Y, Mahoney D J, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol, 2008, 9: 1371-1378.
60. Liao G, Zhang M, Harhaj E W, et al. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem, 2004, 279: 26243-26250.
61. Vallabhapurapu S, Matsuzawa A, Zhang W, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol, 2008, 9: 1364-13670.
62. He J Q, Zarnegar B, Oganesyan G, et al. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med, 2006, 203: 2413-2418.
63. Varfolomeev E, Blankenship J W, Wayson S M, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell, 2007, 131: 669-681.
64. Vince J E, Wong W W, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell, 2007, 131: 682-693.
65. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev, 2009, 227: 75-86.
66. Kawai T, Sato S, Ishii K J, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol, 2004, 5: 1061-1068.
67. Hoshino K, Sugiyama T, Matsumoto M, et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature, 2006, 440: 949-953.
68. Uematsu S, Sato S, Yamamoto M, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med, 2005, 201: 915-923.
69. Katherine A F, Sarah M M, Kerrie L F, et al. v IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol, 2003, 4: 491-496.
70. Hemmi H, Takeuchi O, Sato S, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med, 2004, 199: 1641-1650.
71. Perry A K, Chow E K, Goodnough J B, et al. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med, 2004, 199: 1651-1658.
72. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity, 2006, 25: 349-360.
73. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature, 2005, 434: 772-777.
74. Oganesyan G, Saha S K, Guo B, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature, 2005, 439: 208-211.
75. Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol, 2005, 6: 981-988.
76. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature, 2005, 437: 1167-1172.
77. Seth R B, Sun L, Ea C K, et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell, 2005, 122: 669-682.
78. Xu L G, Wang Y Y, Han K J, et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell, 2005, 19: 727-740.
79. Saha S K, Pietras E M, He J Q, et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J, 2006, 25: 3257-3263.
80. Kayagaki N, Phung Q, Chan S, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science, 2007, 318: 1628-1632.
81. Wang C, Chen T, Zhang J, et al. The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon. Nat Immunol, 2009, 10: 744-752.